TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report)’s stock price traded down 3.6% during mid-day trading on Monday . The company traded as low as $3.22 and last traded at $3.23. 97,864 shares were traded during mid-day trading, a decline of 100% from the average session volume of 32,220,806 shares. The stock had previously closed at $3.35.
TNF Pharmaceuticals Trading Down 3.6%
The stock has a market capitalization of $5.97 million, a PE ratio of -0.01 and a beta of 2.04. The firm has a 50-day moving average price of $3.80 and a 200-day moving average price of $3.91.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
Further Reading
- Five stocks we like better than TNF Pharmaceuticals
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
